{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/menieres-disease/prescribing-information/prochlorperazine/","result":{"pageContext":{"chapter":{"id":"584ce48e-7ea7-5ee0-874b-1c99ccbdb8fa","slug":"prochlorperazine","fullItemName":"Prochlorperazine","depth":2,"htmlHeader":"<!-- begin field 0f9ffb0c-069b-4fec-9590-c215d8893609 --><h2>Prochlorperazine</h2><!-- end field 0f9ffb0c-069b-4fec-9590-c215d8893609 -->","summary":"","htmlStringContent":"<!-- begin item 1f32fff4-170e-4ff3-b540-981cdd82d973 --><!-- end item 1f32fff4-170e-4ff3-b540-981cdd82d973 -->","topic":{"id":"c2b20ab8-7e5a-5868-9804-8a9d6a2cb567","topicId":"193a65ca-1981-44e6-a5d3-781aa5010b2c","topicName":"Meniere's disease","slug":"menieres-disease","lastRevised":"Last revised in November 2017","chapters":[{"id":"16b06288-e565-5867-9311-37b626851eb0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"47494f3b-a0fd-53b2-8613-2cd38f1a11dd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"371c2958-24a9-5d9c-ae14-b7539d491674","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d13d990c-bded-5655-aa70-40268a150cbd","slug":"changes","fullItemName":"Changes"},{"id":"c184f0c8-2419-565f-ab73-a1a5591fc29d","slug":"update","fullItemName":"Update"}]},{"id":"9c1b726a-8066-5632-89ef-7764e1edd1d3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8ee08c5c-67dd-57f0-b666-7d874024d8ed","slug":"goals","fullItemName":"Goals"},{"id":"7fd84935-e76b-56af-b285-b58ed2a8ecc2","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"981ad1f7-1003-50fc-8e49-411ea1ff34d4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4307ba4c-2b7b-54c0-9103-71e4a18f16ac","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"416a0198-b8a8-5272-8684-3aa5a380fc74","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2221f812-317a-569e-a4bc-0183f833d0f7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"272bf558-6edb-531a-a2d4-4b19639383ad","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"25e37eb8-40b6-5b11-b9d3-4fe5378e1524","slug":"definition","fullItemName":"Definition"},{"id":"65d7cb18-66af-5447-8401-2c8e24d64dd4","slug":"cause","fullItemName":"Cause"},{"id":"4f2a2237-790f-5b99-9650-34b58a75512e","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ed8dbd0f-7c6b-53bf-a2b9-77006586ab7e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a4342e8b-12e6-56d8-a716-190cac3ce652","slug":"complications","fullItemName":"Complications"},{"id":"5b357eed-7df9-57ca-9c0d-0511ecf6f601","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"318e7c3d-c3c6-5a60-be9d-9179e643d3fb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0ae90882-dae2-56da-b987-8bca0eefb6b3","slug":"suspecting-menieres-disease","fullItemName":"Suspecting Meniere's disease"},{"id":"7fc93a60-260c-5030-a14e-d6375907f198","slug":"making-a-diagnosis","fullItemName":"Making a diagnosis"},{"id":"73c5b8af-f846-541f-a7d9-48e2c6b9679c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3f2772f3-1ee5-5ca8-8c0c-bb2454b53670","fullItemName":"Management","slug":"management","subChapters":[{"id":"ed30823a-3e70-58a0-9411-f17351fb2c44","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"0b1be20b-b94c-56a6-a221-cbea038b74ec","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"2054a7c4-97a4-57e7-a3de-05ea67cfa502","slug":"betahistine","fullItemName":"Betahistine"},{"id":"2e656ebe-784a-562f-8aca-85a4aa0f56bb","slug":"cinnarizine","fullItemName":"Cinnarizine"},{"id":"73881eee-9a58-575f-9d06-545fa1f67335","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"584ce48e-7ea7-5ee0-874b-1c99ccbdb8fa","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"0c353f7c-323c-5e3b-9872-1e6533f5abad","slug":"promethazine-teoclate","fullItemName":"Promethazine teoclate"}]},{"id":"5de25a19-1810-510b-ba6b-c9b9979fb4c6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f893c00d-a15b-572d-8042-6164f0ee4141","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"18f58ee1-0ff6-5c45-b4a3-5f2f22070e03","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"41de5190-f85f-57eb-81a1-fa4aad3af7b5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"9e4161b0-4719-5539-99e5-e094855a17d0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5a5f7056-1236-5638-904d-dce7e2b843af","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2b63dcde-7589-5a5a-b219-7f2ff2e0b527","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8a8e9bf2-d409-5815-8467-31e3a6379930","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0b1be20b-b94c-56a6-a221-cbea038b74ec","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"377e527e-679b-58df-a490-2b296b0c1c7e","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field c99cf524-f9ed-46e0-b3de-a81000efaa76 --><h3>What dosage of prochlorperazine should I prescribe?</h3><!-- end field c99cf524-f9ed-46e0-b3de-a81000efaa76 -->","summary":"","htmlStringContent":"<!-- begin item c6b8d1d5-1387-452d-b5a6-a81000efa7b1 --><!-- begin field 3e4a4487-b30f-428b-aa11-a81000efaa76 --><ul><li>For vertigo and Meniere's disease, prescribe prochlorperazine 5 mg orally three times a day (maximum dose 30 mg daily) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2017b</a>]. </li><li>If the oral route is not appropriate, consider prescribing either:<ul><li>Prochlorperazine buccal tablets 3–6 mg twice a day (to be placed high in the buccal cavity and allowed to dissolve) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2016b</a>], or </li><li>A one-off dose of prochlorperazine 12.5 mg by deep intramuscular injection followed by oral medication after an interval of 6 hours, if required [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2015c</a>].</li></ul></li></ul><!-- end field 3e4a4487-b30f-428b-aa11-a81000efaa76 --><!-- end item c6b8d1d5-1387-452d-b5a6-a81000efa7b1 -->","subChapters":[]},{"id":"b1b7a030-254a-52b6-83b3-18026113e0a9","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 8c896a14-05bb-4b51-972d-a81000f01c46 --><h3>What are the contraindications and cautions when prescribing prochlorperazine?</h3><!-- end field 8c896a14-05bb-4b51-972d-a81000f01c46 -->","summary":"","htmlStringContent":"<!-- begin item 44eace21-22ac-4471-9c4d-a81000f01a76 --><!-- begin field 13a7067f-b834-4441-b689-a81000f01c46 --><ul><li><strong>Do not prescribe prochlorperazine</strong> <strong>to p</strong><strong>eople with:</strong><ul><li>Hypersensitivity to prochlorperazine or its excipients.</li><li>Agranulocytosis.</li><li>A history of angle closure glaucoma.</li><li>Prostate hypertrophy.</li><li>Myasthenia gravis.</li><li>Heart failure.</li><li>Hypothyroidism.</li><li>Parkinson's disease.</li><li>History of jaundice.</li><li>Liver or renal dysfunction.</li><li>Phaeochromocytoma.</li></ul></li><li><strong>Prescribe prochlorperazine with caution to:</strong><ul><li>People with epilepsy or a history of seizures — close monitoring is required in this group of people as prochlorperazine may lower the seizure threshold.</li><li>Elderly people — use with caution, especially during very hot or cold weather due to the risk of hyper- or hypothermia.</li><li>People with cardiovascular disease or family history of QT prolongation — cases of QT interval prolongation have been very rarely reported with prochlorperazine. An alternative anti-emetic should be considered for people with predisposing factors for ventricular arrhythmias, or they should be carefully monitored (check electrolytes and ECG), particularly during the initial phase of treatment.<ul><li>Cardiac disease; metabolic abnormalities such as hypokalaemia, hypocalcaemia, or hypomagnesaemia; starvation; alcohol misuse; and concurrent treatment with other drugs known to prolong the QT interval may predispose people to ventricular arrhythmias.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BNF 74, 2017</a>] </p><!-- end field 13a7067f-b834-4441-b689-a81000f01c46 --><!-- end item 44eace21-22ac-4471-9c4d-a81000f01a76 -->","subChapters":[]},{"id":"c8d04548-3544-5932-b9d3-049a707cb87c","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 140637fe-05f4-40a5-9538-a81000f059a0 --><h3>What are the adverse effects of prochlorperazine?</h3><!-- end field 140637fe-05f4-40a5-9538-a81000f059a0 -->","summary":"","htmlStringContent":"<!-- begin item 53cfd96c-eb38-4ee5-9a2f-a81000f0577a --><!-- begin field 00a83a02-d132-4713-94c3-a81000f059a0 --><ul><li><strong>Extrapyramidal symptoms</strong><ul><li>These depend on the dose and the susceptibility of the individual person:<ul><li>Parkinsonian symptoms (including tremor) may occur more commonly in adults or the elderly and may appear gradually.</li><li>Dystonia (abnormal face and body movements) and dyskinesia are more common in young people and can occur after only a few doses.</li><li>Akathisia (restlessness) characteristically occurs after large initial doses.</li><li>Tardive dyskinesia (rhythmic, involuntary movements of the tongue, face, and jaw) usually develops on long-term treatment or with high doses.</li></ul></li></ul></li><li><strong>Endocrine disorders</strong><ul><li>Hyperprolactinaemia which may result in galactorrhoea, gynaecomastia, impotence, and amenorrhoea has been reported following treatment with prochlorperazine.</li></ul></li><li><strong>Cardiac disorders</strong><ul><li>Cardiac arrhythmias, including atrial arrhythmia, atrioventricular block, ventricular fibrillation, and ventricular tachycardia (rare), have been reported. QT prolongation, sudden death, cardiac arrest, and Torsades de points have also occurred following treatment with prochlorperazine.</li><li>Pre-existing cardiac disease, family history of QT prolongation, increasing age, hypokalaemia, and concurrent use of other drugs known to prolong the QT interval may increase the likelihood of these effects.</li></ul></li><li><strong>Blood and lymphatic system disorders</strong><ul><li>Mild leucopenia occurs in up to 30% of people on high doses of prochlorperazine for a prolonged period of time.</li><li>Agranulocytosis may occur rarely, but it is not related to the dose. If unexplained infections or fever occur, immediate haematological investigation is required.</li><li>Cases of venous thromboembolism have also been reported with prochlorperazine.</li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>Neurological disorders — drowsiness, apathy, agitation, excitement, insomnia, convulsions, dizziness, headache, and confusion.</li><li>Antimuscarinic effects — dry mouth, constipation, difficulty with micturition, blurred vision, and precipitation of angle-closure glaucoma (very rare).</li><li>Skin and tissue disorders — photosensitization, contact sensitization, rashes, and purplish pigmentation of the skin.</li><li>Hepatobiliary disorders — jaundice (including cholestatic).</li><li>Eye disorders — corneal and lens opacities and purplish pigmentation of the cornea, conjunctiva, and retina.</li><li>Neuroleptic malignant syndrome (potentially fatal) — symptoms include changes in conscious level and mental status, unexplained fever, hyperthermia, autonomic dysfunction, and muscle rigidity.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BNF 74, 2017</a>]</p><!-- end field 00a83a02-d132-4713-94c3-a81000f059a0 --><!-- end item 53cfd96c-eb38-4ee5-9a2f-a81000f0577a -->","subChapters":[]},{"id":"a217dd65-2d77-5f20-bc3d-c7703d2d0cb1","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field c3f69c30-c050-4a12-b250-a81000f08e61 --><h3>What drug interactions occur with prochlorperazine?</h3><!-- end field c3f69c30-c050-4a12-b250-a81000f08e61 -->","summary":"","htmlStringContent":"<!-- begin item c268bb57-2da3-439c-bd07-a81000f08cd6 --><!-- begin field 344224a2-9c83-4740-afa1-a81000f08e61 --><ul><li><strong>Alcohol </strong>— advise the person to avoid taking alcohol whilst taking prochlorperazine.<ul><li>The sedative effects of alcohol on driving and operating heavy machinery may be enhanced by prochlorperazine.</li></ul></li><li><strong>Antimuscarinic drugs </strong>— there is a risk of increased antimuscarinic adverse effects when prochlorperazine is given with other antimuscarinic drugs.</li><li><strong>Antiepileptic drugs</strong> — concurrent use of prochlorperazine and antiepileptic drugs may lower the seizure threshold because of liver enzyme induction. </li><li><strong>Antihypertensive drugs —</strong> the hypotensive effect of most antihypertensive drugs (particularly alpha-adrenoceptor blockers and calcium channel blockers) may be increased by prochlorperazine.</li><li><strong>Cimetidine</strong> — plasma concentrations of prochlorperazine may be increased or decreased by cimetidine. Excessive sedation may occur and it may be necessary to reduce the dose of prochlorperazine.</li><li><strong>Central nervous system (CNS) depressants </strong>— the CNS depressant actions of prochlorperazine may be increased by barbiturates, opioid analgesics, anxiolytics, and hypnotics, raising the risk of respiratory depression.</li><li><strong>Drugs which prolong the QT interval </strong>— there is an increased risk of ventricular arrhythmias when prochlorperazine is used concurrently with drugs that prolong the QT interval, for example anti-arrhythmics, sotalol, antidepressants (tricyclics, citalopram, and escitalopram), antihistamines (terfenadine), methadone, and risperidone.</li><li><strong>Lithium </strong>— there is an increased risk of extrapyramidal adverse effects and possibly neurotoxicity when prochlorperazine is given with lithium. </li><li><strong>Sulphonylureas </strong>— the hypoglycaemic effect of sulfonylureas (such as gliclazide) may be antagonized by prochlorperazine. Dose adjustment of the sulfonylurea may be required.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2017b</a>]</p><!-- end field 344224a2-9c83-4740-afa1-a81000f08e61 --><!-- end item c268bb57-2da3-439c-bd07-a81000f08cd6 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}